94.40MMarket Cap-1565P/E (TTM)
2.250High2.130Low128.05KVolume2.250Open2.240Pre Close278.27KTurnover0.52%Turnover RatioLossP/E (Static)43.70MShares8.19452wk High0.91P/B53.47MFloat Cap1.57452wk Low--Dividend TTM24.76MShs Float23.990Historical High--Div YieldTTM5.36%Amplitude1.390Historical Low2.173Avg Price1Lot Size
Werewolf Therapeutics Stock Forum
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three obje...
NEWS
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, ...
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...
No comment yet